Drugs for Ductal Carcinoma in Situ (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 89)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Ropivacaine |
Approved |
Phase 4 |
|
84057-95-4 |
71273 175805 |
Synonyms:
(-)-1-Propyl-2',6'-dimethyl-2-piperidylcarboxyanilide
(-)-1-Propyl-2',6'-pipecoloxylidide
(+-)-Ropivacaine
(S)-(-)-1-Propyl-2',6'-pipecoloxylidide
(S)-(−)-1-PROPYL-2',6'-PIPECOLOXYLIDIDE
(S)-ROPIVACAINE
1 Propyl 2',6' pipecoloxylidide
1-Propyl-2',6'-dimethyl-2-piperidylcarboxyanilide
1-Propyl-2',6'-pipecoloxylidide
1-propyl-2',6'-pipecoloxylidide|AL-381|LEA-103|Naropin®|ropivacaine hydrochloride
AL-381
DL-Ropivacaine
LEA 103
LEA-103
L-N-N-Propylpipecolate-2,6-xylidide
L-N-N-Propylpipecolic acid-2,6-xylidide
Naropeine
|
Naropin
N-N-Propylpipecolate-2,6-xylidide
N-N-Propylpipecolic acid-2,6-xylidide
Racemic ropivacaine
rac-Ropivacaine
Ropivacaina
Ropivacaina [INN-Spanish]
Ropivacaina [Spanish]
Ropivacaine
Ropivacaine [INN]
Ropivacaine hydrochloride
Ropivacaine monohydrochloride
Ropivacaine monohydrochloride, (S)-isomer
Ropivacainum
Ropivacainum [INN-Latin]
S-Ropivacaine
|
|
2 |
|
Ondansetron |
Approved, Withdrawn |
Phase 4 |
|
99614-02-5 |
4595 |
Synonyms:
A04AA01
Apo-ondansetron
DESMETHYLONDANSETRON
Dihydrate, ondansetron monohydrochloride
EUR-1025
GR-38032
GR-38032F
GR-38032F/GR-38032|ondansetron hydrochloride|ondansetron hydrochloride dihydrate|Zofran®
Hydrochloride, ondansetron
Monohydrochloride dihydrate, ondansetron
Monohydrochloride, ondansetron
Novo-ondansetron
ONDANSETRON
Ondansetron hydrochloride
|
Ondansetron monohydrochloride
Ondansetron monohydrochloride dihydrate
Ondansetron, (+,-)-isomer
Ondansetron, (R)-isomer
Ondansetron, (S)-isomer
PHL-ondansetron
PMS-ondansetron
Ratio-ondansetron
Sandoz ondansetron
Zofran
Zofran odt
Zophren
Zudan
ZUPLENZ
|
|
3 |
|
Sufentanil |
Approved, Investigational |
Phase 4 |
|
56030-54-7 |
41693 |
Synonyms:
Chronogesic
Citrate, sufentanil
Curasan brand OF sufentanil citrate
Curasan, sufentanil
Hameln brand OF sufentanil citrate
IDS-NS-001
Janssen brand OF sufentanil citrate
N-(4-(Methoxymethyl)-1-(2-(2-thienyl)ethyl)-4-piperidinyl)-N-phenylpropanamide
N-(4-(Methoxymethyl)-1-(2-(2-thienyl)ethyl)-4-piperidyl)propionanilide
R-30730
Ratiopharm brand OF sufentanil citrate
Sufenta
Sufenta®|sufentanil citrate|Zalviso®
Sufentanil
Sufentanil citrate
|
Sufentanil curasan
Sufentanil hameln
Sufentanil ratiopharm
Sufentanil-hameln
SufentanilHameln
Sufentanilo
Sufentanil-ratiopharm
SufentanilRatiopharm
Sufentanilum
Sufentanilum [INN-Latin]
Sufentanyl
Sulfentanil
Sulfentanil Citrate
Sulfentanyl
Taylor brand OF sufentanil citrate
|
|
4 |
|
Dsuvia |
|
Phase 4 |
|
|
|
5 |
|
Anesthetics, Local |
|
Phase 4 |
|
|
|
6 |
|
Anesthetics, Intravenous |
|
Phase 4 |
|
|
|
7 |
|
Anesthetics, General |
|
Phase 4 |
|
|
|
8 |
|
Analgesics, Opioid |
|
Phase 4 |
|
|
|
9 |
|
Medroxyprogesterone acetate |
Approved, Investigational |
Phase 3 |
|
520-85-4, 71-58-9 |
6279 10631 |
Synonyms:
(6ALPHA)-17-(ACETYLOXY)-6-METHYLPREG-4-ENE-3,20-DIONE
(6α)-17-(Acetyloxy)-6-methylpreg-4-ene-3,20-dione
17 alpha Hydroxy 6 alpha methylprogesterone
17 alpha-Hydroxy-6 alpha-methylprogesterone
17-ACETOXY-6ALPHA-METHYLPROGESTERONE
17-ACETOXY-6Α-METHYLPROGESTERONE
17a-Hydroxy-6a-methylprogesterone
17alpha-Hydroxy-6alpha-methylprogesterone
17ALPHA-HYDROXY-6ALPHA-METHYLPROGESTERONE ACETATE
17-Hydroxy-6alpha-methyl-pregn-4-ene-3,20-dione
17-Hydroxy-6alpha-methylprogesterone
17-Hydroxy-6a-methyl-pregn-4-ene-3,20-dione
17-Hydroxy-6a-methylprogesterone
17-Hydroxy-6α-methyl-pregn-4-ene-3,20-dione
17-Hydroxy-6α-methylprogesterone
17Α-hydroxy-6α-methylprogesterone
17Α-HYDROXY-6Α-METHYLPROGESTERONE ACETATE
6ALPHA-METHYL-17-ACETOXY PROGESTERONE
6-ALPHA-METHYL-17-ALPHA-ACETOXYPROGESTERONE
6alpha-Methyl-17alpha-hydroxyprogesterone
6ALPHA-METHYL-17ALPHA-HYDROXYPROGESTERONE ACETATE
6-ALPHA-METHYL-17-ALPHA-HYDROXYPROGESTERONE ACETATE
6alpha-Methyl-4-pregnen-17alpha-ol-3,20-dione
6ALPHA-METHYL-4-PREGNENE-3,20-DION-17ALPHA-OL ACETATE
6a-Methyl-17a-hydroxyprogesterone
6a-Methyl-4-pregnen-17a-ol-3,20-dione
6Α-METHYL-17-ACETOXY PROGESTERONE
6Α-methyl-17α-hydroxyprogesterone
6Α-METHYL-17Α-HYDROXYPROGESTERONE ACETATE
6Α-methyl-4-pregnen-17α-ol-3,20-dione
6α-Methyl-4-pregnene-3,20-dion-17α-ol acetate
ADGYN MEDRO
AMEN
Aragest
Aragest 5
Asconale
CBP-1011
CLIMANOR
Clinofem
Clinovir
Colirest
CURRETAB
CYCRIN
Depo-Clinovir
Depo-Prodasone
Depo-Progestin
DEPO-PROGEVERA
Depo-Promone
DEPO-PROVERA
DEPO-PROVERA ONCOLOGY
DEPO-SUBQ PROVERA 104
Depot-Medroxyprogesterone acetate
DMPA
FARLUTAL
FARLUTAL 100
FARLUTAL 200
FARLUTAL 250
FARLUTAL 500
Farlutal inyectable
|
Farlutin
Gestapuran
G-Farlutal
Hematrol
Hydroxymethylprogesterone
hydroxymethylprogesterone|MPA
Hysron
Indivina
LUNELLE
Lutopolar
Lutoral
MAP
Med-Pro
Medroprogesterone Acetate
Medrossiprogesterone
Medrossiprogesterone [Dcit]
Medroxiprogesterona
Medroxiprogesterona [INN-Spanish]
MEDROXIPROGESTERONE ACETATE
Medroxiprogesteronum
MEDROXYACETATE PROGESTERONE
Medroxyprogesteron
Medroxyprogesteron acetate
MEDROXYPROGESTERONE
MEDROXYPROGESTERONE 17-ACETATE
MEDROXYPROGESTERONE ACETATE
Medroxyprogesterone strakan brand
Medroxyprogesteronum
Medroxyprogesteronum [INN-Latin]
Meprate
METHYLACETOXYPROGESTERONE
Methylhydroxyprogesterone
METIGESTRONA
MPA
MPA Gyn 5
Nadigest
Nidaxin
Novo-Medrone
NSC-21171
NSC-26386
Oragest
Perlutex
Perlutex Leo
PREMPRO
Prodasone
Progestalfa
Progevera
PROVERA
Proverone
Ralovera
Repromap
Repromix
SAYANA PRESS
Sirprogen
Sodelut G
Strakan brand OF medroxyprogesterone
TV-46046
Veramix
|
|
10 |
|
Trastuzumab |
Approved, Investigational |
Phase 3 |
|
180288-69-1 |
|
Synonyms:
4D5V8
ABP 980
ABP-980
ANTI HER2
D5v8|Herceptin®|R-597
DMB-3111 (TRASTUZUMAB BIOSIMILAR)
EG12014
EG-12014
HERCEPTIN
IG GAMMA-1 CHAIN C REGION
KADCYLA
|
R-597
RHUMAB HER2
SYD977
SYD-977
TRASTUZUMAB
TRASTUZUMAB BETA
trastuzumab-anns
trastuzumab-dkst
trastuzumab-dttb
trastuzumab-pkrb
trastuzumab-qyyp
|
|
11 |
|
Anastrozole |
Approved, Investigational |
Phase 3 |
|
120511-73-1 |
2187 |
Synonyms:
2,2'-(5-(1H-1,2,4-Triazol-1-ylmethyl)-1,3-phenylene)bis(2-methylpropionitrile)
a,a,Alpha',alpha'-tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-m-benzenediacetonitrile
alpha,alpha,Alpha',alpha'-tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-m-benzenediacetonitrile
Anastrazole
Anastrole
Anastrozol
ANASTROZOLE
Arimidex
Arimidex®
Astra brand OF anastrozole
|
AstraZeneca brand OF anastrozole
ICI D1033
ICI-D1033
NASTROSA
ZD1033
ZD-1033
Zeneca brand OF anastrozole
Zeneca ZD 1033
Α,α,alpha',alpha'-tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-m-benzenediacetonitrile
α,α,α',α'-Tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-m-benzenediacetonitrile
|
|
12 |
|
Letrozole |
Approved, Investigational |
Phase 3 |
|
112809-51-5 |
3902 |
Synonyms:
4,4'-(1H-1,2,4-Triazol-1-yl-methylene)-bis(benzonitrile)
CGS-20267
FEM345
Femara
Fémara
|
Femara®
Letrozol
LETROZOLE
Novartis brand OF letrozole
|
|
13 |
|
Exemestane |
Approved, Investigational |
Phase 3 |
|
107868-30-4 |
60198 |
Synonyms:
6-Methyleneandrosta-1,4-diene-3,17-dione
Aromasil
Aromasin
Aromasin®|FCE-24304
Aromasine
Examestane
Exemestance
|
EXEMESTANE
Exemestano
Exemestano [INN-Spanish]
Exemestanum
Exemestanum [INN-Latin]
FCE-24304
PNU-155971
|
|
14 |
|
Sodium citrate |
Approved, Investigational |
Phase 3 |
|
68-04-2 |
23431961 |
Synonyms:
Anhydrous sodium citrate
Anhydrous trisodium citrate
Citric acid, trisodium salt
Natrii citras
Natrocitral
Sodium citrate anhydrous
Sodium citrate, anhydrous
|
Sodium citrate,anhydrous
Sodium citric acid
Trisodium 2-hydroxypropane-1,2,3-tricarboxylate
trisodium citrate anhydrous
Trisodium citrate, anhydrous
Trisodium-citrate
|
|
15 |
|
Citric acid |
Approved, Nutraceutical, Vet_approved |
Phase 3 |
|
77-92-9 |
311 |
Synonyms:
2-hydroxy-1,2,3-propanetricarboxyic acid
2-Hydroxy-1,2,3-propanetricarboxylate
2-Hydroxy-1,2,3-propanetricarboxylic acid
2-Hydroxytricarballylate
2-Hydroxytricarballylic acid
3-Carboxy-3-hydroxypentane-1,5-dioate
3-Carboxy-3-hydroxypentane-1,5-dioic acid
Acid monohydrate, citric
ácido cítrico
Acidum citricum
Aciletten
Anhydrous citrate
Anhydrous citric acid
beta-Hydroxytricarballylate
beta-Hydroxytricarballylic acid
Chemfill
Citraclean
Citrate
Citrate anhydrous
Citretten
CITRIC ACID
Citric acid anhydrous
CITRIC ACID HYDRATE
Citric acid monoglyceride
|
Citric acid monohydrate
Citric acid, anhydrous
Citric acid,anhydrous
Citro
Citronensaeure
Citronensäure
e 330
e330
E-330
FEMA NO. 2306
H3Cit
Hydrocerol a
INS NO.330
INS-330
Kyselina citronova
Monohydrate, citric acid
NSC-112226
NSC-30279
NSC-626579
Suby g
Uralyt u
UROLOGIC G
Uro-trainer
|
|
16 |
|
Contraceptives, Oral |
|
Phase 3 |
|
|
|
17 |
|
Contraceptive Agents |
|
Phase 3 |
|
|
|
18 |
|
Estrogens, Conjugated (USP) |
|
Phase 3 |
|
|
|
19 |
|
Contraceptives, Oral, Hormonal |
|
Phase 3 |
|
|
|
20 |
|
Contraceptive Agents, Male |
|
Phase 3 |
|
|
|
21 |
|
Immunologic Factors |
|
Phase 3 |
|
|
|
22 |
|
Aromatase Inhibitors |
|
Phase 3 |
|
|
|
23 |
|
Immunoglobulins, Intravenous |
|
Phase 3 |
|
|
|
24 |
|
Immunoglobulins |
|
Phase 3 |
|
|
|
25 |
|
Antibodies, Monoclonal |
|
Phase 3 |
|
|
|
26 |
|
Antibodies |
|
Phase 3 |
|
|
|
27 |
|
Trastuzumab biosimilar HLX02 |
|
Phase 3 |
|
|
|
28 |
|
Citrate |
|
Phase 3 |
|
|
|
29 |
|
Carboplatin |
Approved |
Phase 2 |
|
41575-94-4 |
10339178 38904 |
Synonyms:
Blastocarb
Carboplat
CARBOPLATIN
Carboplatine
Carboplatino
Carbosin
Carbotec
Cbdca
CIS-(1,1-CYCLOBUTANEDICARBOXYLATO)DIAMMINEPLATINUM(II)
CIS-DIAMMINE(1,1-CYCLOBUTANEDICARBOXYLATO)PLATINUM
CIS-DIAMMINE(1,1-CYCLOBUTANEDICARBOXYLATO)PLATINUM(II)
|
Ercar
JM 8
JM8
JM-8
Nealorin
Neocarbo
NSC-201345
NSC-241240
PARAPLATIN
Paraplatin-AQ
Ribocarbo
|
|
30 |
|
Progesterone |
Approved, Vet_approved |
Phase 2 |
|
57-83-0 |
5994 |
Synonyms:
(1S,2R,10S,11S,14S,15S)-14-ACETYL-2,15-DIMETHYLTETRACYCLO[8.7.0.0^{2,7}.0^{11,15}]HEPTADEC-6-EN-5-ONE
(8S,9S,10R,13S,14S,17S)-17-ACETYL-10,13-DIMETHYL-1,2,6,7,8,9,11,12,14,15,16,17-DODECAHYDROCYCLOPENTA[A]PHENANTHREN-3-ONE
(8S,9S,10R,13S,14S,17S)-17-ETHANOYL-10,13-DIMETHYL-1,2,6,7,8,9,11,12,14,15,16,17-DODECAHYDROCYCLOPENTA[A]PHENANTHREN-3-ONE
(S)-4-PREGNENE-3,20-DIONE
(S)-PREGN-4-EN-3,20-DIONE
(S)-PROGESTERONE
17ALPHA-PROGESTERONE
17A-PROGESTERONE
17Α-PROGESTERONE
3,20-PREGNENE-4
4-PREGNEN-3,20-DIONE
4-PREGNENE-3,20-DIONE
AGOLUTIN
AKROLUTIN
Amen
BETA-PROGESTERONE
BIO-LUTON
CIDR
COLPROSTERONE
CORLUTIN
CORLUTINA
CORLUVITE
CORPORIN
CORPUS LUTEUM HORMONE
CRINONE
CRINONE PROGESTERONE GEL
CURRETAB
CYCLOGEST
CYCLOGESTERIN
Cycrin
D4-PREGNENE-3,20-DIONE
DELALUTIN
DELTA(4)-PREGNENE-3,20-DIONE
DELTA(SUP 4)-PREGNENE-3,20-DIONE
DURAPROGEN
ENDOMETRIN
ESTIMA
FLAVOLUTAN
FOLOGENON
Gelbkoerperhormon
GELBKÖRPERHORMON
GESTEROL
GESTEROL 100
GESTEROL 50
GESTIRON
GESTONE
GESTORMONE
GESTRON
GLANDUCORPIN
GYNLUTIN
GYNOLUTON
GYNOLUTONE
HORMOFLAVEINE
HORMOLUTON
Hydroxyprogesterone caproate
Hydroxyprogesterone caproic acid
LINGUSORBS
LIPO-LUTIN
LUCORTEUM
LUCORTEUM SOL
LUGESTERON
LUTEAL HORMONE
Luteinique
LUTEOCRIN NORMALE
LUTEODYN
LUTEOGAN
LUTEOHORMONE
LUTEOL
LUTEOPUR
LUTEOSAN
LUTEOSTAB
LUTEOVIS
LUTEUM
LUTEX
LUTIDON
LUTIGEST
|
Lutin
LUTOCICLINA
LUTOCUCLIN M
LUTOCYCLIN
LUTOCYCLIN M
LUTOCYLIN
LUTOCYLOL
LUTOFORM
LUTOGYL
LUTOGYNON
LUTREN
LUTROMONE
MEMBRETTES
METHYLPREGNONE
MPA
NALUTRON
NSC-64377
NSC-9704
PERCUTACRINE
PERCUTACRINE LUTEINIQUE
PIAPONON
PRANONE
PREGN-4-EN-3,20-DIONE
PREGN-4-ENE-3,20-DIONE
PREGNENE-3,20-DIONE
PREGNENEDIONE
PRIMOLUT
PROCHIEVE
PROGEFFIK
PROGEKAN
PROGESTA-CARE
PROGESTAN
PROGESTASERT
PROGESTEROL
PROGESTERON
PROGESTERONA
Progesterona [INN-Spanish]
PROGESTERONE
PROGESTÉRONE
Progesterone, (13 alpha,17 alpha)-(+-)-isomer
Progesterone, (17 alpha)-isomer
Progesterone, (9 beta,10 alpha)-isomer
PROGESTERONUM
Progesteronum [INN-Latin]
PROGESTIN
PROGESTOGEL
PROGESTOL
PROGESTON
PROGESTONE
PROGESTOSOL
PROGESTRON
PROGESTRONOL
PROJESTAJECT
PROLETS
PROLIDON
PROLUTIN
PROLUTON
PROLUTONE
PROMETRIUM
Prometrium®|Utrogestan®
PRONTOGEST
PROTORMONE
REGUMATE
SERENITY FOR WOMEN
SYNGESTERONE
SYNGESTRETS
SYNGESTRONE
SYNOVEX S
SYNTOLUTAN
Thiuram E
Thiuranide
U 3672
UTROGEST
UTROGESTAN
VITARRINE
Δ(4)-pregnene-3,20-dione
|
|
31 |
|
Chloroquine |
Approved, Investigational, Vet_approved |
Phase 1, Phase 2 |
|
54-05-7 |
2719 |
Synonyms:
3377 RP opalate
7-CHLORO-4-{[4-(DIETHYLAMINO)-1-METHYLBUTYL]AMINO}QUINOLINIUM
Amokin
Aralen
Aralen HCl
Aralen®|chloraquine|Malaquin®
Arechin
Arechine
Arequin
Arthrochin
Artrichin
Avlochlor
Avloclor
Bemaco
Bemaphate
Bemaphic acid
Bemasulph
Benaquin
Bipiquin
Capquin
Chemochin
Chingamin
Chloraquine
Chlorochin
Chlorochine
Chloroquina
Chloroquine
Chloroquine Phosphate
Chloroquine sulfate
Chloroquine sulphate
Chloroquinium
Chloroquinum
Chlorquin
Cidanchin
Clorochina
Cloroquina
Cocartrit
Dawaquin
Delagil
Dichinalex
Elestol
Gontochin
Heliopar
|
Hydroxychloroquine Sulfate
Imagon
Iroquine
Khingamin
Klorokin
Lapaquin
MALAQUIN
Malaren
Malarex
Mesylith
N(4)-(7-Chloro-4-quinolinyl)-N(1),N(1)-diethyl-1,4-pentanediamine
N4-(7-chloro-4-quinolinyl)-N1,N1-diethyl-1,4-pentanediamine
Neochin
Nivachine
Nivaquine
Nivaquine b
NSC-187208
Pfizerquine
Plaquenil
Quinachlor
Quinagamin
Quinagamine
Quinercyl
Quingamine
Quinilon
Quinoscan
Resochen
Resochin
Resoquina
Resoquine
Reumachlor
Reumaquin
Roquine
Sanoquin
Silbesan
Siragan
Solprina
Sopaquin
Sulfate, chloroquine
Sulphate, chloroquine
Tanakan
Tresochin
Trochin
|
|
32 |
|
Zoledronic acid |
Approved |
Phase 2 |
|
118072-93-8 |
68740 |
Synonyms:
(1-Hydroxy-2-(1H-imidazol-1-yl)ethylidene)bisphosphonate
(1-Hydroxy-2-(1H-imidazol-1-yl)ethylidene)bisphosphonic acid
(1-Hydroxy-2-imidazol-1-ylethylidene)diphosphonate
(1-Hydroxy-2-imidazol-1-ylethylidene)diphosphonic acid
2-(Imidazol-1-yl)-1-hydroxyethylidene-1,1-bisphosphonic acid
ácido zoledrónico
ACLASTA
Aclasta®|CGP-42446|CGP-42446A|Reclast®|zoledronate|Zometa®
ANHYDROUS ZOLEDRONIC ACID
CGP-42446
CGP-42446A
Novartis brand OF zoledronic acid
|
Reclast
ZERLINDA
ZOL
ZOL446
ZOLEDRONATE
Zoledronic acid
Zoledronic acid anhydrous
ZOLEDRONIC ACID HYDRATE
ZOLEDRONIC ACID MONOHYDRATE
ZOLEDRONIC ACID, ANHYDROUS
Zometa
Zometa Concentrate
|
|
33 |
|
Estradiol |
Approved, Investigational, Vet_approved |
Phase 2 |
|
50-28-2 |
5757 |
Synonyms:
(+)-3,17B-ESTRADIOL
(17b)-Estra-1,3,5(10)-triene-3,17-diol
(17BETA)-ESTRA-1,3,5(10)-TRIENE-3,17-DIOL
(17Β)-ESTRA-1,3,5(10)-TRIENE-3,17-DIOL
(1S,10R,11S,14S,15S)-15-METHYLTETRACYCLO[8.7.0.0^{2,7}.0^{11,15}]HEPTADECA-2,4,6-TRIENE-5,14-DIOL
(8R,9S,13S,14S,17S)-13-METHYL-6,7,8,9,11,12,14,15,16,17-DECAHYDROCYCLOPENTA[A]PHENANTHRENE-3,17-DIOL
[<sup>3</sup>H]-estradiol|[<sup>3</sup>H]-estrogen|[<sup>3</sup>H]E2|[<sup>3</sup>H]estradiol
13B-METHYL-1,3,5(10)-GONATRIENE-3,17B-OL
17 beta Estradiol
17 beta Oestradiol
17 beta-Estradiol
17 beta-Oestradiol
17b Oestradiol
17b-Estra-1,3,5(10)-triene-3,17-diol
17B-ESTRADIOL
17BETA OESTRADIOL
17BETA-ESTRA-1,3,5(10)-TRIENE-3,17-DIOL
17BETA-ESTRADIOL
17BETA-OESTRADIOL
17B-OESTRADIOL
17Β oestradiol
17Β-ESTRA-1,3,5(10)-TRIENE-3,17-DIOL
17β-estradiol
17Β-OESTRADIOL
3,17B-DIHYDROXYESTRA-1,3,5(10)-TRIENE
3,17B-ESTRADIOL
3,17-EPIDIHYDROXYESTRATRIENE
ADGYN ESTRO
AERODIOL
AGOFOLLIN
ALFATRADIOL
ALORA
ALTRAD
AMNESTROGEN
AQUADIOL
AQUAGEN
BARDIOL
BEDOL
B-ESTRADIOL
BETA-ESTRADIOL
CIS-ESTRADIOL
CLIMADERM
CLIMARA
CLIMARA PRO
COMPUDOSE
CORPAGEN
Delestrogen
DELTA-ESTRADIOL
DELTA-OESTRADIOL
DEPO-ESTRADIOL
DERMESTRIL
DERMESTRIL 100
DERMESTRIL 25
DERMESTRIL 50
DERMESTRIL SEPTEM 25
DERMESTRIL SEPTEM 50
DERMESTRIL SEPTEM 75
DESTRADIOL
D-ESTRADIOL
DIHYDROFOLLICULAR HORMONE
DIHYDROFOLLICULIN
DIHYDROMENFORMON
DIHYDROTHEELIN
DIHYDRO-THEELIN
DIHYDROXYESTRIN
DIMENFORMON
DIOGYN
DIOGYNETS
DIVIGEL
D-OESTRADIOL
E2
E2|estrogen|oestrodiol|oestrogen
E-CYPIONATE
ELESTRIM
ELESTRIN
ELLESTE SOLO
ELLESTE SOLO MX 40
ELLESTE SOLO MX 80
ENCORE
EPIESTRIOL 50
ESCLIM
ESTRA-1,3,5(10)-TRIENE-3,17B-DIOL
ESTRACE
ESTRADERM
ESTRADERM MX 100
ESTRADERM MX 25
ESTRADERM MX 50
ESTRADERM MX 75
ESTRADERM TTS
ESTRADERM TTS 100
ESTRADERM TTS 25
ESTRADERM TTS 50
ESTRADIOL
Estradiol 17 alpha
Estradiol 17 beta
Estradiol 17beta
Estradiol anhydrous
ESTRADIOL HEMIHYDRATE
Estradiol hemihydrate, (17 alpha)-isomer
Estradiol monohydrate
Estradiol orion brand
Estradiol valerate
Estradiol valeriante
|
Estradiol, (-)-isomer
Estradiol, (+-)-isomer
Estradiol, (16 alpha,17 alpha)-isomer
Estradiol, (16 alpha,17 beta)-isomer
Estradiol, (17-alpha)-isomer
Estradiol, (8 alpha,17 beta)-(+-)-isomer
Estradiol, (8 alpha,17 beta)-isomer
Estradiol, (9 beta,17 alpha)-isomer
Estradiol, (9 beta,17 beta)-isomer
Estradiol, monosodium salt
Estradiol, sodium salt
Estradiol-17 alpha
Estradiol-17 beta
Estradiol-17b
ESTRADIOL-17BETA
ESTRADIOL-17-BETA
Estradiol-17β
ESTRADIOLUM
ESTRADOT
ESTRALDINE
ESTRASORB
ESTRING
ESTRING VAGINAL RING
ESTROCLIM
ESTROCLIM 50
ESTROGEL
ESTROGEL HBF
ESTROGEN
ESTROVITE
EVAMIST
EVOREL
EVOREL 100
EVOREL 25
EVOREL 50
EVOREL 75
FEMATRIX 40
FEMATRIX 80
FEMESTRAL
FEMOGEN
FEMPATCH
FEMSEVEN 100
FEMSEVEN 50
FEMSEVEN 75
FOLLICYCLIN
GELESTRA
GINOSEDOL
GVNODIOL
GYNERGON
GYNODIOL
GYNOESTRYL
GYNOGEN
IMVEXXY
INNOFEM
LAMDIOL
MACRODIOL
MENOREST
MENOREST 37.5
MENOREST 50
MENOREST 75
MENORING 50
MENOSTAR
MINIVELLE
NORDICOL
Novartis pharmaceuticals brand OF estradiol
NSC-20293
NSC-9895
OESCLIM
OESTERGON
OESTRA-1,3,5(10)-TRIENE-3,17B-DIOL
OESTRADIOL
OESTRODIOL
OESTROGEL
OESTROGEN
OESTROGLANDOL
Orion brand OF estradiol
OVAHORMON
OVASTEROL
OVASTEVOL
OVOCYCLIN
OVOCYLIN
PERLATANOL
PRIMOFOL
PROFOLIOL
PROFOLIOL B
PROGYNON
Progynon depot
PROGYNON DH
Progynon-depot
Progynova
PROGYNOVA TS
SANDRENA
SANDRENA 1
SYNDIOL
SYSTEN
VAGIFEM
VAGIFEM 18
VAGIFEM 8
VIVELLE
VIVELLE-DOT
WC3011
WC-3011
ZUMENON
Β-estradiol
|
|
34 |
|
Polyestradiol phosphate |
Approved |
Phase 2 |
|
28014-46-2 |
|
Synonyms:
(17-beta)-Estra-1,3,5(10)-triene-3,17-diol polymer with phosphoric acid
ESTRADIOL PHOSPHATE
Estradiol phosphate polymer
ESTRADURIN
Fosfato de poliestradiol
LEO-114
Oestradiol phosphate polymer
|
Phosphate de polyestradiol
Poly(estradiol phosphate)
POLYEST PHOS
POLYESTRADIOL PHOS PHOSPHATE
POLYESTRADIOL PHOSPHATE
Polyestradioli phosphas
|
|
35 |
|
Bazedoxifene |
Approved, Investigational |
Phase 2 |
|
198481-32-2 |
154257 |
Synonyms:
BAZEDOXIFENE
Bazedoxifene acetate
BAZEDOXIFENE/CONJUGATED ESTROGENS
Bazedoxifeno
CONBRIZA
|
Conbriza®|TSE-424|Viviant®|WAY-140424
TSE 424
TSE-424
VIVIANT
WAY-140424
|
|
36 |
|
Sargramostim |
Approved, Investigational |
Phase 2 |
|
123774-72-1 |
|
Synonyms:
B1 61.012
B1-61012
LEUKINE
RECOMBINANT GM-CSF
Recombinant human granulocyte-macrophage colony stimulating factor
|
rGM-CSF
RHU GM-CSF
RHU-GM-CSF
SARGRAMOSTIM
|
|
37 |
|
Metformin |
Approved |
Phase 2 |
|
1115-70-4, 657-24-9 |
4091 |
Synonyms:
[<sup>14</sup>C]-metformin
1,1-Dimethyl biguanide
1,1-Dimethylbiguanide
1-CARBAMIMIDAMIDO-N,N-DIMETHYLMETHANIMIDAMIDE
Apo-Metformin
BOLAMYN SR
Diabefagos
Diabex
Diaformin
DIAGEMET XL
Dianben
Dimethylbiguanid
Dimethylbiguanide
Dimethylbiguanidine
Dimethyldiguanide
Dimethylguanylguanidine
DMBG
Fortamet
Gen-Metformin
GLUCAMET 500
GLUCAMET 850
GLUCIENT SR
Glucophage
GLUCOPHAGE SR
GLUCOPHAGE XR
Glumetza
Glycon
GLYFORMIN
HCL, Metformin
Hydrochloride, metformin
JANUMET
LA 6023
LA-6023
|
LEDERMETIN
Meguan
METABET SR
Metformin
Metformin HCL
Metformin hydrochloride
Metformina
Metformine
Metforminum
Metiguanide
METSOL
MILFORM
Mylan-Metformin
N(1),N(1)-Dimethylbiguanide
N,N-Dimethylbiguanide
N,N-Dimethyldiguanide
N,N-Dimethylguanylguanidine
N,N-Dimethylimidodicarbonimidic diamide
N1,N1-Dimethylbiguanide
Novo-Metformin
NSC-91485
Nu-Metformin
Obimet
ORABET
PMS-Metformin
Ran-Metformin
Ratio-Metformin
Riomet
Sandoz Metformin
SUKKARTO SR
Teva-Metformin
XLA399
|
|
38 |
|
Oxytocin |
Approved, Vet_approved |
Phase 2 |
|
50-56-6 |
439302 53477758 |
Synonyms:
(2S)-2-[({1-[(4R,7S,10S,13S,16S,19R)-19-amino-13-[(2S)-butan-2-yl]-6,9,12,15,18-pentahydroxy-10-[2-(C-hydroxycarbonimidoyl)ethyl]-7-[(C-hydroxycarbonimidoyl)methyl]-16-[(4-hydroxyphenyl)methyl]-1,2-dithia-5,8,11,14,17-pentaazacycloicosa-5,8,11,14,17-pentaene-4-carbonyl]pyrrolidin-2-yl}(hydroxy)methylidene)amino]-N-[(C-hydroxycarbonimidoyl)methyl]-4-methylpentanimidate
(Arg8)-vasopressin
(Arg8)-vasotocin
[<sup>3</sup>H]oxytocin
alpha-Hypophamine
Argipressin
Argpressin acetate
Biotinyl-(arg8)-vasopressin
Cys-tyr-ile-GLN-asn-cys-pro-arg-gly-NH2
Cys-tyr-ile-GLN-asn-cys-pro-leu-gly-NH2
Cys-tyr-ile-THR-asn-cys-gly-leu-gly-NH2
Cys-tyr-phe-GLN-asn-cys-pro-arg-gly-NH2
Cys-tyr-phe-GLN-asn-cys-pro-lys-gly-NH2
Disulfide bridge cys1-cys6
Gly-leu-pro-c
Ocytocin
|
ORASTHIN
Oxitocina
OXT
OXYTOCIN
Oxytocin 10 usp units in dextrose 5%
Oxytocin 20 usp units in dextrose 5%
Oxytocin 5 usp units in dextrose 5%
Oxytocin acetate
Oxytocin injection
PITOCIN
SID29217903
SID50111741
SYNTOCINON
SYNTOMETRINE
SYT670
TTA-121
|
|
39 |
|
Ethanol |
Approved |
Phase 2 |
|
64-17-5 |
702 |
Synonyms:
[CH2Me(OH)]
[OEtH]
1-Hydroxyethane
ABLYSINOL
Absolute alcohol
Absolute ethanol
Absolute ethyl alcohol
Aethanol
Aethylalkohol
Alcare hand degermer
Alcohol
Alcohol (ethyl)
Alcohol anhydrous
Alcohol denatured
ALCOHOL DETERMINATION--ALCOHOL
Alcohol etilico
Alcohol etílico
Alcohol, absolute
Alcohol, Dehydrated
Alcohol, denatured
ALCOHOL, DILUTED
Alcohol, ethyl
Alcohol, grain
ALCOHOL, RUBBING
Alcohols
Alcool ethylique
Alcool éthylique
Alcool etilico
Algrain
Alkohol
Alkoholu etylowego
Aminoethanol
Anhydrol
Anhydrous alcohol
Anhydrous ethanol
Äthanol
Äthylalkohol
B3324
Beta-Aminoethanol
Beta-Aminoethyl Alcohol
Beta-Ethanolamine
Beta-Hydroxyethylamine
C2H5OH
Caswell No. 426
Colamine
Cologne spirit
Cologne spirits
Dehydrated alcohol
Dehydrated ethanol
Denatured alcohol
Denatured Alcohol Cd-10
Denatured Alcohol Cd-5
Denatured Alcohol Cd-5a
Denatured Alcohol Sd-1
Denatured Alcohol Sd-13a
Denatured Alcohol Sd-17
Denatured Alcohol Sd-23a
Denatured Alcohol Sd-28
Denatured Alcohol Sd-30
Denatured Alcohol Sd-39b
Denatured Alcohol Sd-39c
Denatured Alcohol Sd-3a
Denatured Alcohol Sd-40m
Denatured ethanol
Desinfektol el
Diluted alcohol
Distilled spirits
DRINKING ALCOHOL
E1510
Envision Conditioner Pdd 9020
ETA
Etanol
|
Etanolo
ETHANOL
éthanol
Ethanol 200 proof
Ethanol Absolute
Ethanol Absolute Bp
Ethanol Anhydrous
Ethanol Extra Pure
Ethanol solution
Ethanol, Silent Spirit
Ethicap
Ethyl alc
Ethyl alcohol
Ethyl Alcohol & Water, 10%
Ethyl Alcohol & Water, 20%
Ethyl Alcohol & Water, 30%
Ethyl Alcohol & Water, 40%
Ethyl Alcohol & Water, 5%
Ethyl Alcohol & Water, 50%
Ethyl Alcohol & Water, 60%
Ethyl Alcohol & Water, 70%
Ethyl Alcohol & Water, 80%
Ethyl Alcohol & Water, 95%
Ethyl Alcohol & Water, 96%
Ethyl alcohol anhydrous
Ethyl alcohol in alcoholic beverages
Ethyl alcohol usp
Ethyl Alcohol, Anhydrous
Ethyl Alcohol, Denatured
Ethyl hydrate
Ethyl hydroxide
Ethylol
Ethylolamine
EtOH
FEMA NO. 2419
Fermentation alcohol
Glycinol
Grain alcohol
Hinetoless
HSDB 531
Hydroxyethane
Infinity pure
Jaysol
Jaysol S
Lux
METHYLATED MINERAL
Methylated Spirit Mineralised
Methylcarbinol
Molasses alcohol
NCI-C03134
NSC-85228
PM-6193-200
Potato alcohol
Punctilious ethyl alcohol
Pyro
Reagent Alcohol
Silent spirit
SPIRIGEL
Spirit
Spirits OF wine
Spiritus vini
Spirt
SURG
Synasol
Tecsol
Tecsol C
Thanol
Thiofaco M-50
Undenatured ethanol
USAF EK-1597
VODKA
|
|
40 |
|
Naltrexone |
Approved, Investigational, Vet_approved |
Phase 2 |
|
16590-41-3 |
5360515 |
Synonyms:
(-)NALTREXONE
(-)naltrexone|naltrexone HCl|ReVia®
17-(Cyclopropylmethyl)-4,5a-epoxy-3,14-dihydroxymorphinan-6-one
17-(Cyclopropylmethyl)-4,5alpha-epoxy-3,14-dihydroxymorphinan-6-one
17-(Cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxymorphinan-6-one
17-(Cyclopropylmethyl)-4,5α-epoxy-3,14-dihydroxymorphinan-6-one
Antaxone
Bristol myers squibb brand OF naltrexone hydrochloride
Bristol-myers squibb brand OF naltrexone hydrochloride
Celupan
Du pont brand OF naltrexone hydrochloride
EN-1639A
EN-1639A [AS HYDROCHLORIDE]
EN-1639A FREE BASE
Hydrochloride, naltrexone
Lacer brand OF naltrexone hydrochloride
Lamepro brand OF naltrexone hydrochloride
MorViva
Nalorex
Naltrexon
Naltrexona
|
Naltrexona [INN-Spanish]
Naltrexone
Naltrexone [Usan:Ban:Inn]
NALTREXONE HCL
Naltrexone hydrochloride
Naltrexonum
Naltrexonum [INN-Latin]
N-Cyclopropylmethyl-14-hydroxydihydromorphinone
N-Cyclopropylmethylnoroxymorphone
Nemexin
Orphan brand OF naltrexone hydrochloride
Pharmazam brand OF naltrexone hydrochloride
PTI-555
ReVia
Schering plough brand OF naltrexone hydrochloride
Schering-plough brand OF naltrexone hydrochloride
TREXAL
Trexan
United drug brand OF naltrexone hydrochloride
Vivitrex
Vivitrol
|
|
41 |
|
Tamoxifen |
Approved |
Phase 2 |
|
10540-29-1, 54965-24-1 |
2733526 |
Synonyms:
(Z)-2-(4-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylethanamine
(Z)-2-(Para-(1,2-diphenyl-1-butenyl)phenoxy)-N,N-dimethylamine
1-Para-b-dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene
1-Para-beta-dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene
1-Para-β-dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene
1-p-b-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene
1-p-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene
1-p-Β-dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene
Apo-tamox
Citofen
Citrate, tamoxifen
Crisafeno
Diemon
EMBLON
FENTAMOX 10
FENTAMOX 20
Gen-tamoxifen
I.C.I.46474 CITRATE
ICI-46474
ICI-46474|Nolvadex®|Soltamox®
ICI-47699
Istubol
KENTADEX
KESSAR
KESSAR 10
KESSAR 20
Noltam
Nolvadex
NOLVADEX D
NOLVADEX FTE
Nolvadex-D
Nourytam
|
Novaldex
Novo-Tamoxifen
OESTRIFEN-10
OESTRIFEN-20
OESTRIFEN-40
Oncomox
PMS-Tamoxifen
Retaxim
Savient brand OF tamoxifen citrate
Soltamox
Tamizam
Tamofen
Tamone
Tamoplex
Tamoxasta
Tamoxen
TAMOXIFEN
Tamoxifen citrate
Tamoxifene
TAMOXIFÈNE
Tamoxifene [INN-French]
Tamoxifeno
Tamoxifeno [INN-Spanish]
Tamoxifenum
Tamoxifenum [INN-Latin]
Tomaxithen
trans-Tamoxifen
Valodex
ZD6157
Zemide
Zitazonium
ZYNOPLEX
|
|
42 |
|
Fulvestrant |
Approved, Investigational |
Phase 2 |
|
129453-61-8 |
17756771 104741 |
Synonyms:
(1S,9R,11S,14S,15S)-15-Methyl-9-[9-(4,4,5,5,5-pentafluoropentanesulphinyl)nonyl]tetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadeca-2,4,6-triene-5,14-diol
(7α,17β)-7-{9-[(4,4,5,5,5-pentafluoropentyl)sulfinyl]nonyl}estra-1(10),2,4-triene-3,17-diol
7-(9-(4,4,5,5,5-Pentafluoropentylsulfinyl)nonyl)estra-1,3,5(10)-triene-3,17-diol
Faslodex
Faslodex®|ICI 182,780|ICI 182780|ICI182780|ZD-9238
|
FULVESTRANT
ICI 182,780
ICI-182780
SID29215034
ZD-9238
|
|
43 |
|
Somatostatin |
Approved, Investigational |
Phase 1, Phase 2 |
|
38916-34-6, 51110-01-1 |
53481605 16129706 |
Synonyms:
(5S,8R,14R,17R,20R,23R,26R,29R,32R,35R)-38-[(2-{[(2R)-2-amino-1-hydroxypropylidene]amino}-1-hydroxyethylidene)amino]-20,35-bis(4-aminobutyl)-14,26,29-tribenzyl-7,10,13,16,19,22,25,28,31,34,37-undecahydroxy-32-[(C-hydroxycarbonimidoyl)methyl]-11-(1-hydroxyethyl)-17-[(1S)-1-hydroxyethyl]-8-(hydroxymethyl)-23-[(1H-indol-3-yl)methyl]-1,2-dithia-6,9,12,15,18,21,24,27,30,33,36-undecaazacyclononatriaconta-6,9,12,15,18,21,24,27,30,33,36-undecaene-5-carboxylate
ALA-GLY-CYCLO-[CYS-LYS-ASN-PHE-PHE-TRP-LYS-THR-PHE-THR-SER-CYS]
Growth hormone-inhibiting hormone (ghih)
L-ALANYLGLYCYL-L-CYSTEINYL-L-LYSYL-L-ASPARAGINYL-L-PHENYLALANYL-L-PHENYLALANYL-L-TRYPTOPHYL-L-LYSYL-L-THREONYL-L-PHENYLALANYL-L-THREONYL-L-SERYL-L-CYSTEINE CYCLIC (3-14) DISULFIDE
SOMATOSTATIN
SOMATOSTATIN-1
SOMATOSTATIN-14
SOMATOSTATINA
|
SOMATOSTATINE
SOMATOSTATINUM
Somatotropin release-inhibiting factor (srif)
Somatotropin release-inhibiting hormone
SRIF-14
SYNTHETIC GROWTH HORMONE RELEASE-INHIBITING HORMONE
SYNTHETIC SOMATOSTATIN-14
|
|
44 |
|
Pasireotide |
Approved |
Phase 1, Phase 2 |
|
396091-73-9 |
56841596 9941444 |
Synonyms:
cyclo((4R)-4-(2-aminoethylcarbamoyloxy)-L-prolyl-L-phenylglycyl-D-tryptophyl-L-lysyl-4-O-benzyl-L-tyrosyl-L- phenylalanyl-)
Pasireotida
Pasireotide
Pasiréotide
pasireotide diaspartate|Signifor®|SOM 230|SOM 320|SOM-230
|
Pasireotidum
SIGNIFOR
SOM 230
SOM230
SOM-230
|
|
45 |
|
Gefitinib |
Approved, Investigational |
Phase 2 |
|
184475-35-2 |
123631 |
Synonyms:
4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline
GEFITINIB
Gefitinibum
Iressa
Iressa®|ZD 1839|ZD1839
Irressat
|
N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-4-quinazolinamide
N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-4-quinazolinamine
ZD 1839
ZD1839
ZD-1839
|
|
46 |
|
Sulforaphane |
Investigational |
Phase 2 |
|
4478-93-7, 142825-10-3 |
5350 |
Synonyms:
(-)-sulforaphane
(R)-sulforaphane
(R)-Sulphoraphane
1-Isothiocyanato-4-methylsulphinylbutane
4-(METHYLSULFINYL)BUTYL ISOTHIOCYANATE
4-methylsulfinylbutyl isothiocyanate
|
4-Methylsulphinylbutyl glucosinolate
Methylsulfoxybutylisothiocyanate
Sulforafan
SULFORAPHANE
Sulphorafan
Sulphoraphane
|
|
47 |
|
Afimoxifene |
Investigational |
Phase 2 |
|
68392-35-8 |
63062 |
Synonyms:
4-(1-(4-(2-(Dimethylamino)ethoxy)phenyl)-2-phenylbut-1-enyl)phenol
4'-Hydroxytamoxifen
4-Hydroxytamoxifen
4-Hydroxy-tamoxifen
4-Hydroxytamoxifen, (e)-isomer
4-Hydroxytamoxifen, (Z)-isomer
4-Monohydroxytamoxifen
4-OHT
|
4-OHT hydrotamoxifen
4oh-Tamoxifen
AFIMOXIFENE
Hydroxytamoxifen
Monohydroxytamoxifen
Para-hydroxytamoxifen
TAMOGEL
Tamoxifen metabolite b
|
|
48 |
|
Molgramostim |
Investigational |
Phase 2 |
|
99283-10-0 |
|
Synonyms:
|
MOLGRAMOSTIM (GENETICAL RECOMBINATION)
SCH-39300
|
|
49 |
|
Analgesics |
|
Phase 1, Phase 2 |
|
|
|
50 |
|
Antirheumatic Agents |
|
Phase 1, Phase 2 |
|
|
|
Interventional clinical trials:
(show top 50)
(show all 111)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
The Ultrasound-guided Multiple-injection Costotransverse Block for Mastectomy and Primary Reconstructive Surgery. A Double Blind, Randomised, Placebo Controlled Trial. |
Unknown status |
NCT04248179 |
Phase 4 |
Ropivacaine injection;Saline 0.9%;Sufentanil and PONV prophylaxis |
2 |
Electronic Xoft Intersociety Brachytherapy Trial |
Completed |
NCT00742222 |
Phase 4 |
|
3 |
Interstitial Brachytherapy Alone Versus External Beam Radiation Therapy After Breast Conserving Surgery for Low-risk Invasive Carcinoma and Low-risk Ductal Carcinoma in Situ (DCIS) of the Female Breast |
Unknown status |
NCT00402519 |
Phase 3 |
|
4 |
Evaluation of a New Intraoperative Gamma Camera for the Sentinel Lymph Node Procedure in Breast Cancer |
Completed |
NCT00757302 |
Phase 3 |
|
5 |
A Phase III Prospective, Randomized, Double-Blind Clinical Trial of Hormone Replacement Therapy In Postmenopausal Women With A History Of Node-Negative Or Ductal Carcinoma In Situ Who Are Receiving Adjuvant Tamoxifen |
Completed |
NCT00026286 |
Phase 3 |
conjugated estrogens;medroxyprogesterone |
6 |
Evaluation of the Diagnostic Performance of MRI±Biopsy to Optimize Resection of Ductal Carcinoma In Situ (DCIS) Breast Cancer |
Completed |
NCT01112254 |
Phase 3 |
|
7 |
A Clinical Trial Comparing Anastrozole With Tamoxifen in Postmenopausal Patients With Ductal Carcinoma in Situ (DCIS) Undergoing Lumpectomy With Radiation Therapy |
Completed |
NCT00053898 |
Phase 3 |
anastrozole;tamoxifen citrate |
8 |
Radiotherapy Versus Low-Dose Tamoxifen Following Breast Conserving Surgery for Low-Risk and Estrogen Receptor-Positive Ductal Carcinoma in Situ of Breast: an International Open-label Randomized Non-inferiority Trial |
Recruiting |
NCT04046159 |
Phase 3 |
Low-dose tamoxifen |
9 |
A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently With Radiation Therapy and Radiation Therapy Alone for Women With HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy |
Active, not recruiting |
NCT00769379 |
Phase 3 |
|
10 |
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer |
Active, not recruiting |
NCT01272037 |
Phase 3 |
Anastrozole;Exemestane;Letrozole;Systemic Chemotherapy;Tamoxifen Citrate |
11 |
A Randomised Phase III Study of Radiation Doses and Fractionation Schedules in Non-low Risk Ductal Carcinoma In Situ (DCIS) of the Breast |
Active, not recruiting |
NCT00470236 |
Phase 3 |
|
12 |
A Phase II Randomized Study Of Intraductal Carboplatin In Women With Ductal Carcinoma In Situ |
Unknown status |
NCT00669747 |
Phase 2 |
Carboplatin i.d. Days 1 & 15;Carboplatin i.d. Day 1; Normal Saline i.d. Day 15;Normal Saline |
13 |
Randomised Trial Testing Observation (No Radiotherapy) Against Radiotherapy In Women With Low-Risk Completely Excised ER Positive Ductal Carcinoma In Situ (DCIS) Of The Breast On Adjuvant Endocrine Therapy |
Unknown status |
NCT00077168 |
Phase 2 |
anastrozole;tamoxifen citrate |
14 |
Preventing Invasive Breast Neoplasia With Chloroquine (PINC) Trial |
Completed |
NCT01023477 |
Phase 1, Phase 2 |
Chloroquine Standard Dose (500mg/week);Chloroquine Low Dose (250mg/week) |
15 |
A Phase II Prospective Pilot Study Evaluating Efficacy of Intravenous Zoledronic Acid Prophylaxis for Prevention of Aromatase Inhibitor Associated Musculoskeletal Symptoms: ZAP-AIMSS Trial |
Completed |
NCT01194440 |
Phase 2 |
letrozole;zoledronic acid |
16 |
Ten Years Results of a Score System to Address Adjuvant Therapies After Breast Conserving Surgery for Ductal Carcinoma in Situ of the Breast. |
Completed |
NCT03002766 |
Phase 2 |
|
17 |
Randomized Phase II Biomarker Pilot Trial of Fluvastatin Use in Women With Ductal Carcinoma in Situ (DCIS) or Stage I Breast Cancer |
Completed |
NCT00416403 |
Phase 2 |
fluvastatin sodium |
18 |
Sulforaphane: A Dietary Histone Deacetylase (HDAC) Inhibitor in Ductal Carcinoma in Situ (DCIS) |
Completed |
NCT00843167 |
Phase 2 |
|
19 |
MammoSite Radiation Therapy System (RTS) as the Sole Radiation Therapy Technique for Ductal Carcinoma In-Situ (DCIS) |
Completed |
NCT00586326 |
Phase 2 |
|
20 |
Pre-surgical Phase IIb Trial of Transdermal 4-Hydroxytamoxifen vs. Oral Tamoxifen in Women With Ductal Carcinoma in Situ of the Breast |
Completed |
NCT00952731 |
Phase 2 |
oral placebo;afimoxifene;tamoxifen citrate;placebo gel |
21 |
Primary Hormonal Therapy for Ductal Carcinoma in Situ: Exploration of a Novel Approach to the Clinical Management of Noninvasive Breast Cancer |
Completed |
NCT00290745 |
Phase 1, Phase 2 |
letrozole;tamoxifen citrate |
22 |
Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women With Estrogen Receptor Positive Ductal Carcinoma In SITU (DCIS) |
Completed |
NCT01439711 |
Phase 2 |
letrozole |
23 |
Positron Emission Tomography/Magnetic Resonance Imaging of Estrogen Receptor Expression n Non-Invasive Breast Cancer |
Recruiting |
NCT03703492 |
Phase 2 |
(18F)FES;Gadobenate dimeglumine |
24 |
Volumetric Lumpectomy Specimen Image Visualization for Intraoperatively Directing Cavity Shaves, a Phase II Study (VIVID) |
Recruiting |
NCT05545150 |
Phase 2 |
|
25 |
Impact of Neoadjuvant Hormonal Therapy on the Surgical Management of Extensive Ductal Carcinomas in Situ |
Recruiting |
NCT04666961 |
Phase 2 |
Tamoxifen 20 mg;Anastrozole 1Mg Tab |
26 |
Intermittent Fasting for Patients With HER2- Negative and ER/PR <10% Breast Cancer and Body Mass Index >= 25 Receiving Neoadjuvant Chemotherapy |
Recruiting |
NCT05327608 |
Phase 2 |
|
27 |
Window Trial of Abemaciclib for Surgically Resectable, Chemotherapy-Resistant, Triple Negative Breast Cancer (a BEAUTY Study*) |
Recruiting |
NCT03979508 |
Phase 2 |
Abemaciclib |
28 |
Pilot Study for the Cryoablation of Ductal Carcinoma In Situ: Subzero and Scorpion Trial |
Recruiting |
NCT05032079 |
Phase 2 |
|
29 |
TBCRC 042 - A Randomized Phase II Window-of-Opportunity Trial of Ruxolitinib in Patients With High Risk and Premalignant Breast Conditions |
Recruiting |
NCT02928978 |
Phase 2 |
Ruxolitinib;Placebo (for Ruxolitinib) |
30 |
SABR-CaRe: A Phase II Randomized Trial of Pre-Operative Stereotactic Ablative Radiation Therapy (SABR) With and Without Caloric Restriction for Early Stage Breast Cancer |
Recruiting |
NCT04959474 |
Phase 2 |
|
31 |
A Large-scale Multicenter Phase II Study Evaluating the Protective Effect of a Tissue Selective Estrogen Complex (TSEC) in Women With Newly Diagnosed Ductal Carcinoma in Situ |
Recruiting |
NCT02694809 |
Phase 2 |
Conjugated Estrogens/Bazedoxifene |
32 |
VADIS Trial: Phase II Trial of Nelipeimut-S Peptide Vaccine in Women With DCIS of the Breast |
Active, not recruiting |
NCT02636582 |
Phase 2 |
Nelipepimut-S Plus GM-CSF Vaccine |
33 |
Wide Excision Alone for DCIS-Grades 1 and 2 |
Active, not recruiting |
NCT00165256 |
Phase 2 |
|
34 |
Randomized Trial of Hypofractionated Whole Breast Irradiation Versus Conventionally Fractionated Whole Breast Irradiation for Ductal Carcinoma In Situ and Early Invasive Breast Cancer |
Active, not recruiting |
NCT01266642 |
Phase 2 |
|
35 |
Time Restricted Eating And Metformin (TEAM) in Invasive Breast Cancer (IBC) or Ductal Carcinoma in Situ (DCIS). A Randomized, Phase IIb, Window of Opportunity Presurgical Trial. |
Not yet recruiting |
NCT05023967 |
Phase 2 |
Extended Release Metformin Hydrochloride |
36 |
Identifying the miR Fingerprint in NAF, Serum, and Tissue in Patients With Ductal Carcinoma in Situ (DCIS) or Invasive Breast Cancer |
Suspended |
NCT02127073 |
Phase 2 |
Intranasal Oxytocin |
37 |
Naltrexone Randomized Controlled Trial for Treatment-Emergent Fatigue in Patients Receiving Radiation Therapy for Breast Cancer |
Terminated |
NCT02137252 |
Phase 2 |
Naltrexone;Sugar Pill |
38 |
An Open Label, Phase 2 Pharmacokinetic Study of Pre-Surgical Intramuscular and Intraductal Fulvestrant in Women With Invasive Breast Cancer or DCIS Undergoing Mastectomy or Lumpectomy |
Terminated |
NCT02540330 |
Phase 2 |
Fulvestrant |
39 |
A Pilot Study of Chemo-prevention of Green Tea in Women With Ductal Carcinoma in Situ (DCIS) |
Terminated |
NCT01060345 |
Phase 2 |
Polyphenon E |
40 |
Breast Cancer Chemoprevention by SOM230, an IGF-I Action Inhibitor |
Terminated |
NCT01372618 |
Phase 1, Phase 2 |
SOM 230 / Pasireotide |
41 |
A Pilot Clinical Trial to Evaluate the Biological Activity of Fulvestrant in Breast Ductal Carcinoma in Situ (DCIS) |
Terminated |
NCT00183963 |
Phase 2 |
Tamoxifen;Fulvestrant |
42 |
A Pilot Study of Stereotactic Accelerated Partial Breast Irradiation (SAPBI) for Post-Menopausal Women (>50 y/o) With Ductal Carcinoma in Situ (DCIS) or Early Stage Breast Cancer |
Terminated |
NCT02365714 |
Phase 1, Phase 2 |
|
43 |
Twin Cities Brachytherapy Study for Ductal Carcinoma in Situ A Phase II Trial |
Terminated |
NCT00290654 |
Phase 2 |
Tamoxifen |
44 |
EGFR Pathway Modulation In Patients With Ductal Carcinoma In Situ Of The Breast |
Terminated |
NCT00082667 |
Phase 2 |
gefitinib |
45 |
Phase I/II Study Evaluating Safety and Effects of Preoperative High-Dose Vitamin D on the Receptors, Biomarkers and Pathological Characteristics of High Grade DCIS or Invasive Breast Cancer. |
Withdrawn |
NCT02856503 |
Phase 1, Phase 2 |
Vitamin D3 |
46 |
Improvement of the Operative Outcome in Patients With Primary VEGF Positive Unifocal Breast Cancer or Ductal Carcinoma in Situ (DCIS) Through the Intraoperative Visualization of the Tumor Using Molecular Imaging and Fluorescent Markers Bevacizumab-IRDye-800CW |
Withdrawn |
NCT05359874 |
Phase 2 |
Bevacizumab-IRDye800CW |
47 |
A Window Trial of Vorinostat in Patients With Ductal Carcinoma in Situ (DCIS) of the Breast |
Completed |
NCT00788112 |
Phase 1 |
vorinostat |
48 |
A Phase IB Trial of Neoadjuvant Multi-Epitope HER2 Peptide Vaccine in Patients With HER2-Expressing DCIS |
Recruiting |
NCT04144023 |
Phase 1 |
|
49 |
A Randomized Clinical Trial Comparing Supplemental Topical Treatments for Acute Radiation Dermatitis in Breast Cancer Patients |
Recruiting |
NCT05340673 |
Phase 1 |
Agent Affecting Integumentary System |
50 |
Phase I Trial of Endoxifen Gel Versus Placebo Gel in Women Undergoing Breast Surgery |
Active, not recruiting |
NCT03317405 |
Phase 1 |
Endoxifen Hydrochloride |
|